Table 5
Newer TB drugs in the clinical pipeline
Compound
Chemical class
Target
Development
stage
Sponsor/coordinator
GSK-286
–
Cholesterol catabolism of
intracellular Mtb
Preclinical
GlaxoSmithKline, TB Drug Accelerator
TBAJ-587
Diarylquinoline
ATP Synthase
Preclinical
TB Alliance, University of Auckland
TBI-223
Oxazolidinone
Protein synthesis
Preclinical
TB Alliance, Institute of Materia Medica
Spectinamide
1810
Spectinamide
Protein synthesis
Preclinical
Microbiotix, Inc.
BTZ-043
Benzothiazinone
DprE1
Phase 1
University of Munich, Hans-Knöll Institute, Jena,
German Center for Infection Research
GSK 070,
GSK3036656
Oxaborole
LeuRS
Phase 1
GlaxoSmithKline
Contezolid
(MRX-4)
Oxazolidinone
Protein synthesis (V region of
23S rRNA)
Phase 1
MicuRx Pharmaceuticals, Inc.
OPC-167832
3,4-dihydrocarbostyril
derivative
DprE1
Phase 1
Otsuka Pharmaceutical Development & Commercial.
Inc.
Macozinone
(MCZ,
PBTZ-169)
Benzothiazinone
DprE1
Phase 1
iM4 TB - Innovative Medicines for Tuberculosis, Bill
& Melinda Gates Found
TBI-166
Riminophenazines
Mycobacterial DNA
Phase 1
Institute of Materia Medica, CAMS & PUMC
TBA-7371
Azaindole
DprE1
Phase 1
TB Alliance
Telacebec
(Q203)
Imidazopyridine amide
qcrB subunit of the
cytochrome bc1 complex
Phase 2
Qurient Co., Ltd, Qurient Co. Ltd./LLC
“Infectex”,
a portfolio
firm of Maxwell Biotech Venture Fund
Sutezolid
Oxazolidinone
Protein synthesis (bacterial
23S rRNA of the 50S subunit)
Phase 2
Sequella, Inc., TB Alliance
Delpazolid
(LCB01-0371)
Oxazolidinone
Protein synthesis (V region of
23S rRNA)
Phase 2
LegoChem Biosciences, Inc.
(continued)
334
A. C. Pushkaran et al.